These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23007440)

  • 1. Physiologically based pharmacokinetic/toxicokinetic modeling.
    Campbell JL; Clewell RA; Gentry PR; Andersen ME; Clewell HJ
    Methods Mol Biol; 2012; 929():439-99. PubMed ID: 23007440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
    Krishnan K; Johanson G
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have physiologically-based pharmacokinetic models delivered?
    Edginton AN; Joshi G
    Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):929-34. PubMed ID: 21762039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling for nanoparticle toxicity study.
    Li M; Reineke J
    Methods Mol Biol; 2012; 926():369-82. PubMed ID: 22975976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach.
    Jonsson F; Johanson G
    Toxicol Appl Pharmacol; 2002 Feb; 179(1):35-49. PubMed ID: 11884235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
    Clewell RA; Clewell HJ
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):129-43. PubMed ID: 18077066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological "constants" for PBPK models for pregnancy.
    Young JF; Branham WS; Sheehan DM; Baker ME; Wosilait WD; Luecke RH
    J Toxicol Environ Health; 1997 Dec; 52(5):385-401. PubMed ID: 9388532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone.
    Gentry PR; Covington TR; Clewell HJ; Anderson ME
    J Toxicol Environ Health A; 2003 Dec; 66(23):2209-25. PubMed ID: 14612334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment.
    Dixit R; Riviere J; Krishnan K; Andersen ME
    J Toxicol Environ Health B Crit Rev; 2003; 6(1):1-40. PubMed ID: 12587252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.